In this edition, novel T-cell therapy effective against common viruses; FDA approves Brukinsa for chronic lymphocytic leukemia; meeting abstracts show inconsistent toxicity reporting and more.
Read the full coverage here:
Novel T-cell therapy effective against common viruses after stem cell transplantation
FDA approves Brukinsa for chronic lymphocytic leukemia, small lymphocytic lymphoma
Review of meeting abstracts shows toxicity reporting inconsistent, incomplete
Cumulative anesthesia exposure linked to impaired neurocognitive function in pediatric ALL
Imetelstat confers durable transfusion independence in lower-risk myelodysplastic syndrome
References:
Alexander S, et al. Abstract 901. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Chin-Yee B, et al. Abstract 129. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2013; New Orleans.
Pfeiffer T, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2415.
